Cancer drug AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation Phase I clinical trial. Additionally, analysis of tumour biopsies obtained from six patients indicates that doxorubicin is being released within the tumour tissue, confirming the tumour targeting potential of the pre|CISION technology. There has […]